.jpg)
evernoa mini
evernoa® mini is a miniaturized, clinically validated diagnostic device that enables continuous monitoring of airway inflammation through exhaled nitric oxide (FeNO) measurement in real-world and home-care settings. Scientifically, it translates decades of evidence supporting FeNO as a biomarker for eosinophilic airway inflammation into a practical, longitudinal monitoring solution.
The core scientific result lies in demonstrating that frequent, real-life FeNO monitoring significantly improves disease control by enabling early detection of inflammation-driven exacerbation risk, better assessment of treatment response and adherence, and more precise patient stratification. Health-economic and clinical studies show that this approach reduces exacerbations, healthcare utilization, and inappropriate escalation to high-cost therapies, while improving quality of life.
By moving airway inflammation assessment from episodic clinical visits to continuous, patient-centered monitoring, evernoa® mini establishes a new paradigm in the management of chronic inflammatory airway diseases.
evernoa® mini is designed for routine clinical and home-based use to enable continuous monitoring of airway inflammation in patients with chronic inflammatory airway diseases, such as asthma. In clinical practice, it supports physicians in treatment optimization, early identification of loss of control, assessment of adherence, and more accurate selection of advanced therapies, including biologics.
In home-care settings, evernoa® mini empowers patients to monitor their disease longitudinally, anticipate exacerbations, and actively engage in their treatment plans, improving adherence and self-management.
At a system level, the product reduces avoidable exacerbations, emergency visits, and hospitalizations, generating significant cost savings and improving healthcare efficiency. The solution is interoperable with existing clinical workflows and digital health infrastructures, enabling scalable deployment across healthcare systems
